San Francisco, California (PRWEB) October 17, 2014
Medrio, a leading provider of eClinical Software as a Service (SaaS) for clinical research, announced today that Atlantic Research Group, a world class CRO helping emerging, agile biopharma firms bring new therapies to market, has joined Medrio’s Partner Program.
“Atlantic Research Group is a great addition to our partner program,” says Scott Weidley, VP of Sales and Marketing at Medrio. “Their extensive areas of clinical expertise allows us to expand our resources, and work with a wider variety of companies running specialized clinical trials.”
The Medrio Partner Program is a collaborative effort that aligns Medrio resources with trusted contract research organizations (CROs) and consultancies. This program was designed to offer extensive training, sales, and marketing support, and deepen product insights to all partners.
“We entered into this partnership with Medrio because our project teams love their system and our corporate philosophies align well,” says Hunter Walker, CTO. “Both companies are nimble and strive to deploy innovative solutions that deliver maximum value to sponsors, both small and large.
Since 2005, Medrio, a SaaS company based out of the SF Bay Area, has offered an integrated eClinical Software platform with a fully hosted Electronic Data Capture (EDC) system. This revolutionary advancement drastically reduces study timelines and costs by giving study managers even more control over their studies. By simplifying and streamlining online research, without the need for any custom development, Medrio eClinical software fast tracks studies allowing them to be completed in days instead of weeks. Medrio's global customers include 12 of the top 20 global biopharmaceutical companies and 3 of the top 10 CROs.
For more information about Medrio, please visit: http://www.medrio.com
About Atlantic Research Group
Based in Charlottesville, VA the Atlantic Research Group (ARG) is one of the fastest growing and most successful full-service CROs dedicated to agile and emerging biopharmaceutical companies. ARG has helped research sponsors in clinical trials of patients at more than 5000 investigative sites worldwide. With a repeat customer rate of over 90%, ARG has become the preferred provider for nearly a dozen small biotechnology organizations developing everything from orphan status immunology and oncology compounds to pivotal Phase III trials. Since its founding in 2004, ARG has utilized an array of Software-as-a-Service (SaaS) solutions to efficiently execute our sponsors' clinical trials.
For more information about Atlantic Research Group, please visit: http://www.atlanticresearchgroup.com